Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1967 1
1980 1
1982 1
1986 1
1987 1
1994 1
1995 2
2010 1
2011 2
2012 3
2013 4
2014 3
2015 4
2016 1
2017 3
2018 7
2019 9
2020 4
2021 9
2022 7
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y, Kato T, Kobayashi K, Daizumoto K, Fukuhara H, Ohira S, Katayama S, Shimizu R, Takamoto A, Nishimura K, Ikeda K, Nagami T, Hayashida Y, Hirama H, Naito H, Tomida R, Sasaki Y, Yamamoto S, Shimizu S, Sugimoto M; Chu-shikoku Japan Urological Consortium. Tohi Y, et al. Among authors: hirama h. Jpn J Clin Oncol. 2024 Feb 7;54(2):167-174. doi: 10.1093/jjco/hyad143. Jpn J Clin Oncol. 2024. PMID: 37840362
Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.
Taoka R, Kamada M, Izumi K, Tanimoto R, Daizumoto K, Hayashida Y, Uematsu K, Arai H, Sano T, Saito R, Hirama H, Kobayashi T, Honda T, Osaki Y, Abe Y, Naito H, Tohi Y, Matsuoka Y, Kato T, Okazoe H, Ueda N, Sugimoto M. Taoka R, et al. Among authors: hirama h. Int J Clin Oncol. 2024 May;29(5):602-611. doi: 10.1007/s10147-024-02481-8. Epub 2024 Feb 28. Int J Clin Oncol. 2024. PMID: 38418804
Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.
Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Bruinsma SM, et al. Nat Rev Urol. 2017 May;14(5):312-322. doi: 10.1038/nrurol.2017.26. Epub 2017 Mar 14. Nat Rev Urol. 2017. PMID: 28290462 Free article. Review.
[TRENDS IN CARDIO-ANGIOLOGY].
MISE J, SAKAGUCHI R, HIRAMA H. MISE J, et al. Among authors: hirama h. Naika. 1964 Jan;13:4-10. Naika. 1964. PMID: 14110437 Review. Japanese. No abstract available.
Long-term outcomes of the first prospective study of active surveillance for prostate cancer in Japan.
Kato T, Hirama H, Kamoto T, Goto T, Fujimoto H, Sakamoto S, Shinohara N, Egawa S, Kouguchi D, Nakayama M, Hashine K, Shimizu N, Inoue K, Habuchi T, Hioka T, Shiraishi T, Sugimoto M, Kakehi Y. Kato T, et al. Among authors: hirama h. Int J Clin Oncol. 2024 Oct;29(10):1557-1563. doi: 10.1007/s10147-024-02590-4. Epub 2024 Aug 1. Int J Clin Oncol. 2024. PMID: 39085727
Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort.
Marenghi C, Qiu Z, Helleman J, Nieboer D, Rubio-Briones J, Carroll PR, Lee LS, Valdagni R, Boutros PC, Nicolai N; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Marenghi C, et al. Cancers (Basel). 2022 Jul 22;14(15):3558. doi: 10.3390/cancers14153558. Cancers (Basel). 2022. PMID: 35892817 Free PMC article.
Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
Beckmann KR, Bangma CH, Helleman J, Bjartell A, Carroll PR, Morgan T, Nieboer D, Santaolalla A, Trock BJ, Valdagni R, Roobol MJ; Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium. Beckmann KR, et al. Prostate. 2022 May;82(7):876-879. doi: 10.1002/pros.24330. Epub 2022 Mar 7. Prostate. 2022. PMID: 35254666 Free PMC article.
Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN.
Kato T, Hirama H, Mitsuzuka K, Maruyama S, Sasaki H, Saito T, Matsumoto R, Sakamoto S, Sakai Y, Fukuhara H, Naya Y, Tsukino H, Hara I, Ogawa O, Hashine K, Fumimasa F, Yokomizo A, Tohi Y, Kakehi Y, Sugimoto M. Kato T, et al. Among authors: hirama h. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):666-671. doi: 10.1038/s41391-021-00422-4. Epub 2021 Jul 12. Prostate Cancer Prostatic Dis. 2022. PMID: 34253849
58 results